Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil
E. White (Ann Arbor, Michigan, United States of America), B. Crestani (Paris, France), A. Günther (Gießen, Germany), T. Maher (London, United Kingdom), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), M. Kolb (Hamilton, Ontario, Canada)
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. White (Ann Arbor, Michigan, United States of America), B. Crestani (Paris, France), A. Günther (Gießen, Germany), T. Maher (London, United Kingdom), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), M. Kolb (Hamilton, Ontario, Canada). Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil. 1923
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: